Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPPLE T1D: NNC0361-0041 in Type 1 Diabetes
NCT04279613Phase 1Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2020
- Primary completion
- Aug 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing NNC0361-0041 with Placebo (2 arms). Primary endpoint: Adverse Events at 16 weeks. Started Nov 2020; status: completed.
02
Drugs
NNC0361-0041
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04279613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279613.